Week in Review: Korea's SK Biopharma Acquires Radiopharmaceutical in $571 Million Deal

Deals and Financings

• South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal;
• Beijing Biocytogen will use its RenLite® platform to discover novel antibody therapeutics for SOTIO Biotech of Prague in a $325 agreement;
• Beijing’s Sino Biological, a biological research reagents/CRO company, completed a $48 million takeover of Vancouver’s SignalChem, a company that offers bioactive enzymes;
• AusperBio, a Hangzhou-San Francisco biotech, booked $37 million in a Series A financing for its novel oligonucleotide and targeted delivery technologies;
• Shanghai’s Rona Therapeutics, a nucleic acid drug R&D company, completed a $35 million Series A+ financing to advance its pipeline of RNA candidates;
• Shanghai's Elpiscience has filed for a Hong Kong IPO to develop drugs for tumor microenvironments that are aimed at improving the efficacy of immunotherapies;
• Legend Biotech, a Nanjing-New Jersey cell therapy company, was rumored to have received a takeover bid, though its parent, GenScript, claims not to know anything about the offer;

Trials and Approvals

• Shanghai’s Everest reported China's NMPA accepted the filing of a supplemental NDA for full approval of Nefecon®, a first-in-disease IgA nephropathy therapy;
• Fujirebio Diagnostics, a global medical diagnostics company, will have access to samples from Alzheimer’s patients in a Phase III trial of an AirBio therapy for AD.
  
  Share this with colleagues: